tradingkey.logo


Dr Reddy's Laboratories Ltd

RDY
14.200USD
+0.260+1.87%
āļ›āļīāļ” 12/19, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
11.82BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
17.32P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Dr Reddy's Laboratories Ltd āļšāļĢāļīāļĐāļąāļ—

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

āļ‚āđ‰āļ­āļĄāļđāļĨ Dr Reddy's Laboratories Ltd


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™RDY
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Dr Reddy's Laboratories Ltd
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļJan 01, 1986
āļ‹āļĩāļ­āļĩāđ‚āļ­Aghanian (Patrick)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™27811
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒDepository Receipt
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Jan 01
āļ—āļĩāđˆāļ­āļĒāļđāđˆ8-2-337, Road No.3 Banjara Hills
āđ€āļĄāļ·āļ­āļ‡HYDERABAD
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX NASDAQ Basic NYSE
āļ›āļĢāļ°āđ€āļ—āļĻIndia
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ500-034
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ914049002900
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.drreddys.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™RDY
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļJan 01, 1986
āļ‹āļĩāļ­āļĩāđ‚āļ­Aghanian (Patrick)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Dr Reddy's Laboratories Ltd


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Deepak Sapra
Mr. Deepak Sapra
Chief Executive Officer - API and Services
Chief Executive Officer - API and Services
--
--
Mr. Sanjiv Soshil Mehta
Mr. Sanjiv Soshil Mehta
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Phanimitra (Phani) B
Mr. Phanimitra (Phani) B
Chief Digital and Information Officer
Chief Digital and Information Officer
--
--
Mr. Mannam Venkata Narasimham
Mr. Mannam Venkata Narasimham
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Richa Periwal
Ms. Richa Periwal
Investor Relations
Investor Relations
--
--
Kodumudi Pranatharthiharan Krishnan
Kodumudi Pranatharthiharan Krishnan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. K. Randhir Singh
Mr. K. Randhir Singh
Compliance Officer, Company Secretary, Head - CSR
Compliance Officer, Company Secretary, Head - CSR
--
--
Mr. Kallam Satish Reddy
Mr. Kallam Satish Reddy
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Chan (Penny) Wan
Ms. Chan (Penny) Wan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Arun Madhavan Kumar
Mr. Arun Madhavan Kumar
Non-Executive Independent Director
Non-Executive Independent Director
--
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Deepak Sapra
Mr. Deepak Sapra
Chief Executive Officer - API and Services
Chief Executive Officer - API and Services
--
--
Mr. Sanjiv Soshil Mehta
Mr. Sanjiv Soshil Mehta
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Phanimitra (Phani) B
Mr. Phanimitra (Phani) B
Chief Digital and Information Officer
Chief Digital and Information Officer
--
--
Mr. Mannam Venkata Narasimham
Mr. Mannam Venkata Narasimham
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Richa Periwal
Ms. Richa Periwal
Investor Relations
Investor Relations
--
--
Kodumudi Pranatharthiharan Krishnan
Kodumudi Pranatharthiharan Krishnan
Non-Executive Independent Director
Non-Executive Independent Director
--
--

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 6 āļ•.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 6 āļ•.āļ„.
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļĒāļąāļ‡āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāđ€āļ›āļīāļ”āđ€āļœāļĒāļˆāļēāļāļ—āļēāļ‡āļšāļĢāļīāļĐāļąāļ—
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
United States
427.18M
42.77%
Other
309.06M
30.94%
India
179.87M
18.01%
Russia
82.79M
8.29%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļĒāļąāļ‡āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāđ€āļ›āļīāļ”āđ€āļœāļĒāļˆāļēāļāļ—āļēāļ‡āļšāļĢāļīāļĐāļąāļ—

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 11 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 11 āļ˜.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Robeco Institutional Asset Management B.V.
1.57%
Aperio Group, LLC
1.20%
RBC Global Asset Management (UK) Limited
1.17%
Renaissance Technologies LLC
1.05%
Aikya Investment Management Limited
0.81%
āļ­āļ·āđˆāļ™ āđ†
94.20%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Robeco Institutional Asset Management B.V.
1.57%
Aperio Group, LLC
1.20%
RBC Global Asset Management (UK) Limited
1.17%
Renaissance Technologies LLC
1.05%
Aikya Investment Management Limited
0.81%
āļ­āļ·āđˆāļ™ āđ†
94.20%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
6.56%
Investment Advisor/Hedge Fund
4.39%
Hedge Fund
1.20%
Research Firm
1.12%
Pension Fund
0.33%
Family Office
0.19%
Family Office
0.10%
Family Office
0.10%
Bank and Trust
0.08%
āļ­āļ·āđˆāļ™ āđ†
85.93%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 1 āļ•.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 1 āļ•.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q3
516
112.51M
13.51%
-15.88M
2025Q2
504
118.15M
14.19%
-12.22M
2025Q1
506
114.84M
13.80%
-17.55M
2024Q4
478
124.61M
14.96%
-2.62M
2024Q3
462
118.95M
14.28%
-16.57M
2024Q2
445
126.18M
15.15%
-4.51M
2024Q1
437
124.83M
14.99%
-5.58M
2023Q4
427
125.49M
15.07%
-4.37M
2023Q3
406
119.09M
14.31%
-4.07M
2023Q2
397
109.36M
13.16%
-3.97M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
Robeco Institutional Asset Management B.V.
12.16M
1.46%
+1.45M
+13.56%
Jun 30, 2025
Aperio Group, LLC
9.26M
1.11%
+2.30M
+33.13%
Jun 30, 2025
RBC Global Asset Management (UK) Limited
9.33M
1.12%
+281.97K
+3.12%
Jun 30, 2025
Renaissance Technologies LLC
9.01M
1.08%
-182.10K
-1.98%
Jun 30, 2025
Aikya Investment Management Limited
6.35M
0.76%
+154.60K
+2.49%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
5.40M
0.65%
-64.08K
-1.17%
Jun 30, 2025
The Vanguard Group, Inc.
4.98M
0.6%
-27.59K
-0.55%
Jun 30, 2025
Parametric Portfolio Associates LLC
4.28M
0.51%
+631.20K
+17.32%
Jun 30, 2025
State Street Investment Management (US)
4.19M
0.5%
+131.99K
+3.25%
Jun 30, 2025
BNP Paribas Securities Corp. North America
4.01M
0.48%
-569.44K
-12.42%
Jun 30, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
National Security Emerging Markets Index ETF
0.91%
Invesco S&P Emerging Markets Low Volatility ETF
0.39%
Lattice Hartford Multifactor Emerging Markets ETF
0.33%
DFA Dimensional Emerging Markets Value ETF
0.22%
ActivePassive International Equity ETF
0.18%
SPDR MSCI Emerging Markets StrategicFactors ETF
0.15%
DFA Dimensional Emerging Mkts High Proftblty ETF
0.13%
SPDR Portfolio Emerging Markets ETF
0.12%
Avantis Emerging Markets Equity ETF
0.12%
SP Funds S&P World (ex-US) ETF
0.12%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
National Security Emerging Markets Index ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.91%
Invesco S&P Emerging Markets Low Volatility ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.39%
Lattice Hartford Multifactor Emerging Markets ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.33%
DFA Dimensional Emerging Markets Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.22%
ActivePassive International Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.18%
SPDR MSCI Emerging Markets StrategicFactors ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.15%
DFA Dimensional Emerging Mkts High Proftblty ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.13%
SPDR Portfolio Emerging Markets ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.12%
Avantis Emerging Markets Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.12%
SP Funds S&P World (ex-US) ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.12%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 332.70M USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
May 09, 2024
RDY.NB Final Cash Dividend of gross USD 0.476153 paid on Aug 12, 2024 going ex on Jul 30, 2024
Jul 15, 2024
Aug 12, 2024
Jul 30, 2024
May 11, 2023
RDY.NB Final Cash Dividend of gross USD 0.482608 paid on Aug 11, 2023 going ex on Jul 28, 2023
Jul 10, 2023
Aug 11, 2023
Jul 28, 2023
May 24, 2022
RDY.NB Final Cash Dividend of gross USD 0.378434 paid on Aug 12, 2022 going ex on Aug 01, 2022
Jul 11, 2022
Aug 12, 2022
Aug 01, 2022
Jun 16, 2021
RDY.NB Final Cash Dividend of gross USD 0.336485 paid on Aug 11, 2021 going ex on Jul 30, 2021
Jul 09, 2021
Aug 11, 2021
Jul 30, 2021
Jun 26, 2020
RDY.NB Final Cash Dividend of gross USD 0.333364 paid on Aug 17, 2020 going ex on Jul 10, 2020
Jul 13, 2020
Aug 17, 2020
Jul 10, 2020

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
Oct 07, 2024
Split
1→5
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
Oct 07, 2024
Split
1→5

āļ„āļģāļ–āļēāļĄāļ—āļĩāđˆāļžāļšāļšāđˆāļ­āļĒ

āđƒāļ„āļĢāļ„āļ·āļ­āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Dr Reddy's Laboratories Ltd?


āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Dr Reddy's Laboratories Ltd āđ„āļ”āđ‰āđāļāđˆ:
Robeco Institutional Asset Management B.V. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 12.16M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 1.46% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
Aperio Group, LLC āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 9.26M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 1.11% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
RBC Global Asset Management (UK) Limited āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 9.33M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 1.12% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
Renaissance Technologies LLC āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 9.01M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 1.08% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
Aikya Investment Management Limited āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 6.35M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 0.76% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”

āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŠāļēāļĄāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Dr Reddy's Laboratories Ltd āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŠāļēāļĄāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Dr Reddy's Laboratories Ltd āđ„āļ”āđ‰āđāļāđˆ
Robeco Institutional Asset Management B.V.
Aperio Group, LLC
RBC Global Asset Management (UK) Limited

āļĄāļĩāļāļĩāđˆāļŠāļ–āļēāļšāļąāļ™āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Dr Reddy's Laboratories Ltd (RDY)?


āļ“ āļ§āļąāļ™āļ—āļĩāđˆ 2025Q3 āļĄāļĩāļŠāļ–āļēāļšāļąāļ™āļˆāļģāļ™āļ§āļ™ 516 āđāļŦāđˆāļ‡āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Dr Reddy's Laboratories Ltd āđ‚āļ”āļĒāļĄāļĩāļĄāļđāļĨāļ„āđˆāļēāļĢāļ§āļĄāļ›āļĢāļ°āļĄāļēāļ“ 112.51M āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 13.51% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ” āđ€āļĄāļ·āđˆāļ­āđ€āļ—āļĩāļĒāļšāļāļąāļšāļ§āļąāļ™āļ—āļĩāđˆ 2025Q2 āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™āđ„āļ”āđ‰āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™ -0.68%

āđāļŦāļĨāđˆāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŦāļĨāļąāļāļ‚āļ­āļ‡ Dr Reddy's Laboratories Ltd āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āđ€āļĄāļ·āđˆāļ­āļ§āļąāļ™āļ—āļĩāđˆ FY2026Q1 āļ˜āļļāļĢāļāļīāļˆāļ”āđ‰āļēāļ™ -- āļŠāļĢāđ‰āļēāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŠāļđāļ‡āļŠāļļāļ”āđƒāļŦāđ‰āļāļąāļš Dr Reddy's Laboratories Ltd āļ„āļīāļ”āđ€āļ›āđ‡āļ™āļĄāļđāļĨāļ„āđˆāļē -- āđāļĨāļ°āļ„āļīāļ”āđ€āļ›āđ‡āļ™ --% āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļĢāļ§āļĄ
KeyAI
î™